Concizumab (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Concizumab" in English language version.

refsWebsite

Global rank English rank

1^st place

3,984^th place

2,622^nd place

1,712^th place

1,063^rd place

low place

low place

2,726^th place

1,608^th place

102^nd place

76^th place

canada.ca

"Alhemo Product information". Health Canada. 10 March 2023. Archived from the original on 24 March 2023. Retrieved 9 June 2023.

World Health Organization (2013). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 70". WHO Drug Information. 27 (3). hdl:10665/331167.

"Summary Basis of Decision for Alhemo". Health Canada. 31 May 2023. Archived from the original on 10 March 2024. Retrieved 9 June 2023.

"Alhemo (concizumab injection) Product Monograph" (PDF). Health Canada. Archived (PDF) from the original on 3 March 2024. Retrieved 3 March 2024.

"Alhemo APMDS". Therapeutic Goods Administration (TGA). 29 September 2023. Archived from the original on 10 March 2024. Retrieved 7 March 2024.
"Alhemo (Novo Nordisk Pharmaceuticals Pty Ltd)". Therapeutic Goods Administration (TGA). 28 July 2023. Archived from the original on 10 March 2024. Retrieved 10 September 2023.
"AusPAR: Alhemo". Therapeutic Goods Administration (TGA). 18 March 2024. Retrieved 31 March 2024.

"Alhemo APMDS". Therapeutic Goods Administration (TGA). 29 September 2023. Archived from the original on 10 March 2024. Retrieved 7 March 2024.
"Alhemo (Novo Nordisk Pharmaceuticals Pty Ltd)". Therapeutic Goods Administration (TGA). 28 July 2023. Archived from the original on 10 March 2024. Retrieved 10 September 2023.
"Alhemo Product information". Health Canada. 10 March 2023. Archived from the original on 24 March 2023. Retrieved 9 June 2023.
"Alhemo (concizumab injection) Product Monograph" (PDF). Health Canada. Archived (PDF) from the original on 3 March 2024. Retrieved 3 March 2024.
"Summary Basis of Decision for Alhemo". Health Canada. 31 May 2023. Archived from the original on 10 March 2024. Retrieved 9 June 2023.
"Health Canada approves Alhemo, the first subcutaneous prophylactic treatment for people living with hemophilia B with inhibitors" (Press release). Novo Nordisk Canada. 17 April 2023. Archived from the original on 9 June 2023. Retrieved 9 June 2023 – via Newswire.